NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [TheStreet.com]
NervGen Pharma Corp. - Common stock (NGEN)
Company Research
Source: TheStreet.com
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported its full year 2025 financial results and provided business updates. “2025 was a transformative year for NervGen, but more importantly the SCI community,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen. “We've demonstrated the potential best-in-class profile of NVG-291 and its ability to meaningfully improve the lives of those with chronic tetraplegia in the CONNECT SCI study, and we continue to strengthen our understanding of the breadth and quality of that recovery.” “It is our responsibility now to make the promise of NVG-291 a reality and execute on both its increasingly de-risked late-stage clinical development and commercial potentia
Show less
Read more
Impact Snapshot
Event Time:
NGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGEN alerts
High impacting NervGen Pharma Corp. - Common stock news events
Weekly update
A roundup of the hottest topics
NGEN
News
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswire
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaGlobeNewswire
- The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma FY GAAP EPS of -$0.61 [Seeking Alpha]Seeking Alpha
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
NGEN
Sec Filings
- 3/31/26 - Form 40-F
- 3/13/26 - Form 6-K
- 2/13/26 - Form 6-K
- NGEN's page on the SEC website